The Relative Benefits and Risks of Kratom Derived Products

12:00 – 1:15pm

Click Here or Scan the QR Code to Register!

Join us for an informative webinar examining the relative benefits and risks of kratom-derived products. This session will provide an overview of natural leaf kratom, mitragynine extracts, and isolated synthetic compounds (7-OH, mitragynine pseudoindoxyl, MGM-15/16), compare their pharmacologic profiles with traditional opioids, review available clinical and anecdotal data on potential risks and benefits, and discuss regulatory strategies aimed at reducing public health harms while preserving access to natural leaf kratom.

Learning Objectives:

• Describe the three different types of kratom derived products (natural leaf, mitragynine extracts, and isolated synthetics (7-OH, mitragynine pseudoindoxyl, MGM-15/16)
• Compare and contrast the pharmacologic similarities and differences between kratom derived products and with traditional opioids
• Describe the clinical trial and descriptive (anecdotal) data on kratom derived products to determine the potential risks and benefits
• Describe a regulatory approach to reduce public health risk but maintain access to natural leaf kratom

1 CE Credit (1.0 hour):

• CME pending
• MCBAP pending
• Social Work pending
• Meets DEA Training Requirements

Presenter(s):

• Dr. C. Michael White, Pharm.D., FCP, FCCP, FASHP